Literature DB >> 16679351

Liver fluke-associated and sporadic cholangiocarcinoma: an immunohistochemical study of bile duct, peribiliary gland and tumour cell phenotypes.

N R Hughes1, C Pairojkul, S G Royce, A Clouston, P S Bhathal.   

Abstract

AIM: To compare cell phenotypes displayed by cholangiocarcinomas and adjacent bile duct lesions in patients from an area endemic in liver-fluke infestation and those with sporadic cholangiocarcinoma.
METHODS: 65 fluke-associated and 47 sporadic cholangiocarcinomas and 6 normal livers were studied. Serial paraffin-wax sections were stained immunohistochemically with monoclonal antibodies characterising a Brunner or pyloric gland metaplasia cell phenotype (antigens D10 and 1F6), intestinal goblet cells (antigen 17NM), gastric foveolar apomucin (MUC5AC), a gastrointestinal epithelium cytokeratin (CK20) and the p53 protein.
RESULTS: 60% of the 112 cholangiocarcinomas expressed antigen D10, 68% MUC5AC, 33% antigen 17NM and 20% CK20; 37% showed overexpression of p53. When present together in a cholangiocarcinoma, cancer cells expressing D10 were distinct from those displaying 17NM or MUC5AC. Many more fluke-associated cholangiocarcinomas than sporadic cholangiocarcinomas displayed 17NM and p53 expression. Most cases of hyperplastic and dysplastic biliary epithelium expressed D10 strongly. Pyloric gland metaplasia and peribiliary glands displayed D10 and 1F6, with peribiliary gland hyperplasia more evident in the livers with fluke-associated cholangiocarcinoma; goblet cells in intestinal metaplasia stained for 17NM. No notable association of expression between any two antigens (including p53) was found in the cancers.
CONCLUSIONS: Most cases of dysplastic biliary epithelium and cholangiocarcinoma display a Brunner or pyloric gland cell phenotype and a gastric foveolar cell phenotype. The expression of D10 in hyperplastic and dysplastic epithelium and in cholangiocarcinoma is consistent with a dysplasia-carcinoma sequence. Many more fluke-associated cholangiocarcinomas than sporadic cholangiocarcinoma display an intestinal goblet cell phenotype and overexpress p53, indicating differences in the aetiopathology of the cancers in the two groups of patients.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16679351      PMCID: PMC1861757          DOI: 10.1136/jcp.2005.033712

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  22 in total

1.  Cytokeratin profile relates to histological subtypes and intrahepatic location of intrahepatic cholangiocarcinoma and primary sites of metastatic adenocarcinoma of liver.

Authors:  T Shimonishi; K Miyazaki; Y Nakanuma
Journal:  Histopathology       Date:  2000-07       Impact factor: 5.087

Review 2.  Opisthorchis viverrini infection in northeast Thailand and its relationship to cholangiocarcinoma.

Authors:  M R Haswell-Elkins; S Satarug; D B Elkins
Journal:  J Gastroenterol Hepatol       Date:  1992 Sep-Oct       Impact factor: 4.029

3.  Liver cancer in Thailand. I. A case-control study of cholangiocarcinoma.

Authors:  D M Parkin; P Srivatanakul; M Khlat; D Chenvidhya; P Chotiwan; S Insiripong; K A L'Abbé; C P Wild
Journal:  Int J Cancer       Date:  1991-05-30       Impact factor: 7.396

4.  Significance of intestinal metaplasia for the evolution of cancer in the biliary tract.

Authors:  S Kozuka; M Kurashina; M Tsubone; K Hachisuka; A Yasui
Journal:  Cancer       Date:  1984-11-15       Impact factor: 6.860

5.  Vertebrate phylogeny of antigen D10: identification of a conserved foregut cell lineage.

Authors:  S G Royce; N R Hughes; S Binos; J R Underwood; P S Bhathal
Journal:  Histochem Cell Biol       Date:  2000-08       Impact factor: 4.304

6.  Cytokeratin 7 and 20 expression in cholangiocarcinomas varies along the biliary tract but still differs from that in colorectal carcinoma metastasis.

Authors:  A Rullier; B Le Bail; R Fawaz; J F Blanc; J Saric; P Bioulac-Sage
Journal:  Am J Surg Pathol       Date:  2000-06       Impact factor: 6.394

7.  An immunochemical analysis of the human nuclear phosphoprotein p53. New monoclonal antibodies and epitope mapping using recombinant p53.

Authors:  B Vojtĕsek; J Bártek; C A Midgley; D P Lane
Journal:  J Immunol Methods       Date:  1992-07-06       Impact factor: 2.303

8.  Cytokeratin 20 in human carcinomas. A new histodiagnostic marker detected by monoclonal antibodies.

Authors:  R Moll; A Löwe; J Laufer; W W Franke
Journal:  Am J Pathol       Date:  1992-02       Impact factor: 4.307

9.  Antigen expression in normal and neoplastic colonic mucosa: three tissue-specific antigens using monoclonal antibodies to isolated colonic glands.

Authors:  N R Hughes; R S Walls; R C Newland; J E Payne
Journal:  Cancer Res       Date:  1986-04       Impact factor: 12.701

Review 10.  Cholangiocarcinoma: epidemiology, mechanisms of carcinogenesis and prevention.

Authors:  D M Parkin; H Ohshima; P Srivatanakul; V Vatanasapt
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  1993 Nov-Dec       Impact factor: 4.254

View more
  13 in total

Review 1.  The biliary tree--a reservoir of multipotent stem cells.

Authors:  Vincenzo Cardinale; Yunfang Wang; Guido Carpino; Gemma Mendel; Gianfranco Alpini; Eugenio Gaudio; Lola M Reid; Domenico Alvaro
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2012-02-28       Impact factor: 46.802

Review 2.  Infection with the carcinogenic human liver fluke, Opisthorchis viverrini.

Authors:  Michael J Smout; Banchob Sripa; Thewarach Laha; Jason Mulvenna; Robin B Gasser; Neil D Young; Jeffrey M Bethony; Paul J Brindley; Alex Loukas
Journal:  Mol Biosyst       Date:  2011-02-11

3.  Viable metacercariae of Opisthorchis viverrini in northeastern Thai cyprinid fish dishes--as part of a rational program for control of O. viverrini-associated cholangiocarcinoma.

Authors:  Jiraporn Prasongwatana; Porntip Laummaunwai; Thidarut Boonmars; Somchai Pinlaor
Journal:  Parasitol Res       Date:  2012-10-05       Impact factor: 2.289

4.  Etiological and clinicopathologic characteristics of intrahepatic cholangiocarcinoma in young patients.

Authors:  Hua-Bang Zhou; Hui Wang; Dong-Xun Zhou; Hao Wang; Qing Wang; Shan-Shan Zou; He-Ping Hu
Journal:  World J Gastroenterol       Date:  2010-02-21       Impact factor: 5.742

5.  Biliary epithelial injury-induced regenerative response by IL-33 promotes cholangiocarcinogenesis from peribiliary glands.

Authors:  Hayato Nakagawa; Nobumi Suzuki; Yoshihiro Hirata; Yohko Hikiba; Yoku Hayakawa; Hiroto Kinoshita; Sozaburo Ihara; Koji Uchino; Yuji Nishikawa; Hideaki Ijichi; Motoyuki Otsuka; Junichi Arita; Yoshihiro Sakamoto; Kiyoshi Hasegawa; Norihiro Kokudo; Keisuke Tateishi; Kazuhiko Koike
Journal:  Proc Natl Acad Sci U S A       Date:  2017-04-24       Impact factor: 11.205

Review 6.  Cholangiocarcinoma: lessons from Thailand.

Authors:  Banchob Sripa; Chawalit Pairojkul
Journal:  Curr Opin Gastroenterol       Date:  2008-05       Impact factor: 3.287

7.  Perihilar cholangiocarcinoma arising in hepatitis C virus-related liver cirrhosis with hepatocellular carcinoma.

Authors:  Takahiko Fujii; Yoh Zen; Yasuni Nakanuma
Journal:  J Gastroenterol       Date:  2007-08-24       Impact factor: 7.527

8.  Serum IgG as a Marker for Opisthorchis viverrini-Associated Cholangiocarcinoma Correlated with HER2 Overexpression.

Authors:  Attapol Titapun; Anchalee Techasen; Prakasit Sa-Ngiamwibool; Paiboon Sithithaworn; Vor Luvira; Tharatip Srisuk; Apiwat Jareanrat; Hasaya Dokduang; Watcharin Loilome; Bandit Thinkhamrop; Narong Khuntikeo
Journal:  Int J Gen Med       Date:  2020-11-26

Review 9.  The challenge of cholangiocarcinoma: dissecting the molecular mechanisms of an insidious cancer.

Authors:  Abigail Zabron; Robert J Edwards; Shahid A Khan
Journal:  Dis Model Mech       Date:  2013-03       Impact factor: 5.758

Review 10.  Peribiliary Glands as the Cellular Origin of Biliary Tract Cancer.

Authors:  Hayato Nakagawa; Yuki Hayata; Tomoharu Yamada; Satoshi Kawamura; Nobumi Suzuki; Kazuhiko Koike
Journal:  Int J Mol Sci       Date:  2018-06-12       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.